GlucoTrack(GCTK) - 2025 Q4 - Annual Report

Regulatory Approval and Reimbursement - The Glucotrack CBGM is still under development and is likely to be classified as a Class III device, requiring the PMA process for regulatory approval[56]. - The company plans to leverage successful De Novo clinical trial data for CE Mark certification, which is necessary for marketing in EU member states[60]. - Medicare coverage for CGM systems has been expanded to all patients using insulin, effective April 2023, removing the previous requirement of at least three doses of insulin per day[62]. - The Local Coverage Determination (LCD) allows coverage for patients not taking insulin if they have a history of problematic hypoglycemia[63]. - The company anticipates that sales volumes and prices of the Glucotrack CBGM will largely depend on adequate reimbursement from Medicare and third-party payors[64]. - The reimbursement strategy includes coverage for the product, implantation procedure, and removal and reinsertion procedures[67]. - The company is engaging a reimbursement consultant to analyze the current landscape for CGM technologies and similar cardiovascular devices[66]. - Outside the United States, reimbursement availability varies widely, and an EU reimbursement analysis may begin if the company decides to enter the EU market[68]. - The FDA review process for premarket notifications under section 510(k) typically takes about 90 days, but can be longer if concerns arise[53]. - The company is subject to various regulatory requirements in the U.S. and EU, which can affect the efficiency and timeliness of international market introduction of its devices[51]. Intellectual Property and Competition - The company has strengthened its patent portfolio with the issuance of three U.S. patents related to glucose monitoring technologies, enhancing its competitive position in the market[77][78][79]. - The company is pursuing a proactive intellectual property strategy, including patent filings in multiple jurisdictions, which is critical for protecting its innovations[76]. - The market for continuous glucose monitoring (CGM) devices is highly competitive, with Abbott, DexCom, and Medtronic accounting for the majority of worldwide sales[86]. - The company faces significant competition from established players with greater name recognition, distribution networks, and financial resources[87]. - There is currently one implantable CGM commercially available, which lasts up to 365 days, highlighting the competitive landscape for long-term glucose monitoring solutions[87]. Compliance and Operational Structure - The company may be subject to increased scrutiny and enforcement actions related to healthcare fraud and abuse laws, which could materially affect its operations[73]. - The company is required to safeguard patient information under HIPAA, which may increase compliance costs and affect its ability to market devices[75]. - The company has trademark registrations for Glucotrack® in the U.S. and Europe, supporting its brand recognition[83]. - As of December 31, 2025, the company had fifteen full-time employees, indicating a lean operational structure[93]. - The company is not providing quantitative and qualitative disclosures about market risk as a smaller reporting company[265].